Name | Adenosine |
Synonyms | AR Adenosine D-ADENOSINE ADENINENUCLEOSIDE adenosine free base 9-BETA-D-RIBOFURANOSYLADENINE ADENOSINE extrapure for biochemistry 9-alpha-D-lyxofuranosyl-9H-purin-6-amine 6-Amino-9-(beta-D-ribofuranosyl)9H-purine Adenine riboside, Adenine-9-beta-ribofuranoside 9-β-D-Ribofuranosyladenine, Adenine riboside, Adenine-9-β-D-ribofuranoside (2R,3R,4S,5R)-2-(6-AMINO-PURIN-9-YL)-5-HYDROXYMETHYL-TETRAHYDRO-FURAN-3,4-DIOL |
CAS | 58-61-7 |
EINECS | 200-389-9 |
InChI | InChI=1/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6+,7+,10+/m1/s1 |
InChIKey | OIRDTQYFTABQOQ-KQYNXXCUSA-N |
Molecular Formula | C10H13N5O4 |
Molar Mass | 267.24 |
Density | 1.3382 (rough estimate) |
Melting Point | 234-236 °C (lit.) |
Boling Point | 410.43°C (rough estimate) |
Specific Rotation(α) | D11 -61.7° (c = 0.706 in water); 9D -58.2° (c = 0.658 in water) |
Flash Point | 362.8°C |
Water Solubility | Soluble in water, ammonium hydroxide and dimethyl sulfoxide. Insoluble in ethanol. |
Solubility | Soluble in water, insoluble in alcohol |
Vapor Presure | 3.26E-19mmHg at 25°C |
Appearance | White crystal |
Color | White |
Merck | 14,153 |
BRN | 93029 |
pKa | 3.6, 12.4(at 25℃) |
Storage Condition | 2-8°C |
Stability | Stable. Incompatible with strong oxidizing agents. |
Refractive Index | 1.7610 (estimate) |
MDL | MFCD00005752 |
Physical and Chemical Properties | Colorless needle-like crystals of hemihydrate. |
Use | For the manufacture of ATP, adenosine Arabinoside, coenzyme A, etc |
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S24/25 - Avoid contact with skin and eyes. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
WGK Germany | 2 |
RTECS | AU7175000 |
FLUKA BRAND F CODES | 10-23 |
TSCA | Yes |
HS Code | 29389090 |
Toxicity | LD50 oral in mouse: > 20gm/kg |
atrioventricular block and acute myocardial infarction patients disabled.